We enrolled 2,625 human immunodeficiency virus-infected patients into a randomized trial to assess the efficacy and tolerability of daily vs. thrice-weekly trimethoprim-sulfamethoxazole (160 mg/800 mg) for prophylaxis of Pneumocystis carinii pneumonia (PCP). The rate of PCP was 3.5 and 4.1 per 100 person-years in the daily and thrice-weekly groups, respectively, with a relative risk (RR) of 0.82 (95% confidence interval [CI], 0.61-1.09; P ‫؍‬ .16) (RR of <1.0 favors daily trimethoprimsulfamethoxazole). The RR for PCP determined by on-treatment analysis was 0.59 (P ‫؍‬ .03). The RR for death was 0.91 (P ‫؍‬ .12); for bacterial pneumonia, 0.82 (P ‫؍‬ .06); and for combined PCP and bacterial pneumonia, 0.84 (P ‫؍‬ .04). Discontinuation due to adverse events occurred more commonly in the daily trimethoprim-sulfamethoxazole group (RR, 2.14; 95% CI, 1.73-2.66; P < .001). Overall estimates for efficacy end points favored daily trimethoprim-sulfamethoxazole, although rates of intolerance were higher among patients receiving that dose. Daily trimethoprim-sulfamethoxazole may offer advantages as a first choice for PCP prophylaxis; thrice-weekly dosing is an appropriate option for patients intolerant of the daily dose.
The identification of risk factors for development of Pneumocystis carinii pneumonia (PCP) in HIV-infected persons and the discovery of effective prophylaxis have had a significant impact on clinical practice and patient outcomes [1] . Recent data indicate that even though there has been a significant decrease in the incidence of PCP and other opportunistic infections in association with the use of combination antiretroviral therapy, PCP remains an important complication of HIV disease [2] .
Trimethoprim-sulfamethoxazole is the drug of choice for prevention of PCP [3] . Studies have also suggested additional benefits of trimethoprim-sulfamethoxazole as preventive therapy, including the prevention of bacterial infections and toxoplasmosis [4, 5] . However, intolerance to trimethoprimsulfamethoxazole often necessitates the use of less effective second-line medications for PCP prophylaxis [6, 7] . To decrease rates of adverse events associated with the use of trimethoprim-sulfamethoxazole, lower doses have been used [8] . Whether a lower dose is as effective as the high dose in preventing PCP and other HIV-related conditions while having a better safety profile is uncertain.
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Studies have examined various dosages of trimethoprimsulfamethoxazole, including one single-strength tablet daily or twice daily; one double-strength tablet daily, twice daily, twice weekly, or thrice weekly; and two double-strength tablets thrice weekly [9] . Most studies compared one of these dosages with other agents for PCP prophylaxis, and no study has examined the efficacy of low doses of trimethoprimsulfamethoxazole in secondary prophylaxis [4, 10] . Only three small randomized studies have compared different dosages of trimethoprim-sulfamethoxazole [8, 11, 12] . The combined results of these studies lack adequate power for assessing the relative effectiveness of the different dosages.
To establish the efficacy and safety of different dosages of trimethoprim-sulfamethoxazole, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) conducted a large multicenter study to compare daily with thrice-weekly double-strength trimethoprim-sulfamethoxazole for the primary and secondary prevention of PCP among HIV-infected patients.
Methods
Study population. Patients were enrolled from 20 units of the CPCRA conducting clinical trials in HIV primary care settings in 17 U.S. cities. HIV-infected patients aged 13 years were eligible if they had a history of PCP or a CD4 ϩ lymphocyte count of 0.20 ϫ 10 9 cells/mm 3 or 15% of the total lymphocyte count. Prior or baseline use of trimethoprimsulfamethoxazole was not an exclusion criterion. Patients with a history of treatment-limiting reaction to sulfonamides or trimethoprim were excluded.
Study design. The study was a prospective, randomized, open-label clinical trial. The primary objective was to compare the efficacy of daily vs. thrice-weekly trimethoprim-sulfamethoxazole (one double-strength tablet contains 160 mg of trimethoprim and 800 mg of sulfamethoxazole) in preventing or delaying the onset of confirmed or probable PCP. Patients were randomized in a 1:1 ratio by means of a 4-and 8-permuted block design stratified by unit and history of PCP. The study design included a switchover option to the thriceweekly dosage for patients randomized to daily trimethoprimsulfamethoxazole who developed an adverse event necessitating a dose reduction. Sample size and duration of follow-up were determined to provide 80% power to detect a 50% difference in risk between the treatment groups at a .05 level of significance (two-sided). The 2-year rates of development of PCP while being treated with daily trimethoprim-sulfamethoxazole were assumed to be 7.5% and 12% for primary and secondary prophylaxis groups, respectively. Mortality rates were assumed to be 20% and 40% for the primary and secondary groups, respectively. The study was approved by each unit's institutional review board and patients gave written informed consent.
Study end points and patient follow-up. Investigators were blinded to all interim results, which were reviewed by the National Institute of Allergy and Infectious Diseases Data and Safety Monitoring Board. The primary end point for the study was the development of confirmed or probable PCP. Confirmed PCP required histological or cytological evidence of PCP in bronchoalveolar lavage or lung biopsy specimens or sputum. Probable PCP diagnosis relied on clinical findings, including history of either exertional dyspnea or a nonproductive cough; evidence of diffuse bilateral pulmonary disease on either chest radiographs or gallium scan or abnormal arterial blood gases; and the absence of another diagnosis that accounted for the findings. Possible PCP diagnosis was based on clinical evidence for PCP without fulfillment of above criteria. Details of all PCP events irrespective of classification by the unit were reviewed by a committee unaware of patient's treatment assignment to determine if they met the definitions of confirmed or probable episodes of PCP.
The secondary end points included intolerance of the study drug leading to discontinuation of the assigned dosage (for the daily group, this included switching to thrice-weekly or permanent discontinuation of study-supplied trimethoprim-sulfamethoxazole; for the thrice-weekly group, it was equivalent to permanent discontinuation of study-supplied trimethoprimsulfamethoxazole), development of confirmed or probable toxoplasmosis or extrapulmonary pneumocystosis, and death. Diagnosis of confirmed toxoplasmosis required histological evidence by brain tissue biopsy or autopsy or neurological findings with consistent neuroimaging results suggestive of cerebral toxoplasmosis and a positive result of testing of CSF by PCR for Toxoplasma gondii. Diagnosis of probable toxoplasmosis required all of the following criteria: a change in neurological function, onset of these findings over several days to 1 week, consistent neuroimaging results, positive results of serologic testing, and a response to standard therapy for toxoplasmosis. Information on episodes of bacterial pneumonia reported by the investigators, which were not a predetermined study end point, was reported at the scheduled study visits by use of standardized data collection forms. The combined end point of PCP (confirmed, probable, and possible) or bacterial pneumonia included events indicated on specific data collection forms completed at regular study visits.
All participants were evaluated every 4 months and at the time of suspected end points. The evaluation included assessment of study drug status and a clinical assessment, including new HIV-related diagnoses and adverse events, by a five-grade standardized severity grading devised by the Division of AIDS, National Institute of Allergy and Infectious Diseases; grade 4 indicates a severe or potentially life-threatening event.
Regular study evaluations included an assessment by the research staff of participant adherence with the assigned treatment on the basis of patient self-report. Adherence was reported as "good" if participant indicated that 80% of prescribed drug was taken, "fair" if 50%-79% of prescribed drug was taken, and "poor" if Ͻ50% of prescribed drug was taken. Participants were followed until study closure regardless of whether they were receiving study treatments.
Statistical analyses. Treatment groups were compared by use of Kaplan-Meier event-time curves, log-rank tests, and proportional hazard regression models. Unadjusted and adjusted relative risk estimates for daily vs. thrice-weekly trimethoprim-sulfamethoxazole (relative risk of Ͻ1.0 indicates that the result favors daily trimethoprim-sulfamethoxazole) were obtained from a Cox proportional hazards model. For the former, consistent with randomization, stratification by CP-CRA clinical unit and PCP history was used; for the latter, in addition to these stratifications, covariates corresponding to baseline CD4 ϩ cell count (square root) and history of other AIDS (non-PCP) events were included. Also, the proportional hazards model was used to estimate the PCP risk associated with discontinuation of trimethoprim-sulfamethoxazole. In this analysis, indicators of permanent discontinuation due to adverse events and other causes were included as time-varying covariates; patients were considered "on treatment" until 30 days after trimethoprim-sulfamethoxazole was discontinued. An additional on-treatment analysis for the PCP end point censored patient follow-up 30 days after the initially assigned treatment was discontinued. All P values are two-tailed; all median times account for censoring.
Results

Study Population and Follow-Up
Between August 1992 and August 1995, 2,625 patients were enrolled; 2,212 (84%) received primary and 413 (16%) received secondary prophylaxis (had a history of PCP at baseline). At randomization, 70% of participants were receiving trimethoprim-sulfamethoxazole, 0.7% were receiving dapsone, and 0.4% were receiving pentamidine. At baseline, 71% of the participants were receiving antiretroviral therapy (59% mononucleoside and 12% dual nucleoside therapy). None of the patients were receiving protease inhibitor-or nonnucleoside inhibitor-containing regimens at baseline. At 12 months of follow-up, 8% of participants were receiving protease inhibitor-containing regimens; at 24 months, 5%, and at 36 months, 13% were receiving protease inhibitor-containing regimens. Selected baseline patient characteristics are noted in table 1. The two treatment groups were similar with regard to most baseline characteristics. The mean CD4 ϩ lymphocyte count was significantly lower among those assigned daily trimethoprim-sulfamethoxazole (128 cells/mm 3 ) than among those receiving thrice-weekly treatment (136 cells/mm 3 (P ϭ .05). The adjusted analyses take into account this difference in CD4 ϩ lymphocyte counts. At study closure on 30 September 1996, the median follow-up was 22 months for each treatment group; 3.7% of each group had unknown PCP status and 3.0% in each group had unknown vital status. The median time receiving the assigned study dose was similar for the daily and thrice-weekly groups: 14.3 months and 15.6 months, respectively. Adherence was assessed at 12 months and was reported as good for 85% and 86% of patients assigned daily and thrice-weekly trimethoprim-sulfamethoxazole, respectively, among patients receiving study drug. Adherence was reported as fair for 10% and as poor for 4% of patients in each treatment group.
Overall, 886 patients (68%) assigned daily and 834 patients (64%) assigned thrice-weekly trimethoprim-sulfamethoxazole discontinued the assigned study dosage. Among patients in the daily dosage group, 104 (8%) changed to thrice-weekly treatment. The most common reasons for discontinuation were death (19.6% and 20.3%), patient request (13.8% and 12.6%), and adverse events (19.4% and 9.6%) for patients assigned daily and thrice-weekly treatment, respectively. Of the 426 patients originally assigned to the daily treatment group and the 413 patients assigned to the thrice-weekly group who attended at least one follow-up visit after the discontinuation of assigned study medication, 58% and 63% were receiving trimethoprimsulfamethoxazole, 25% and 24% were receiving dapsone, and 14% were receiving aerosol pentamidine, respectively. At study closure, of 1,510 patients (755 on each arm) who survived, 426 (56.4%) and 479 (63.4%) were receiving their assigned daily and thrice-weekly trimethoprim-sulfamethoxazole, respectively.
Study End Points
PCP.
A confirmed or probable PCP event was noted for 90 patients (3.5 per 100 person-years) assigned daily and for 105 patients (4.1 per 100 person-years) assigned thrice-weekly trimethoprim-sulfamethoxazole. Unadjusted and adjusted relative risks were 0.86 (95% CI, 0.64 -1.14; P ϭ .28) and 0.82 (95% CI, 0.61-1.09; P ϭ .16) (table 2). Throughout this report, relative risks Ͻ1.0 indicate results that favor the daily dosage of trimethoprim-sulfamethoxazole. A total of 111 confirmed PCP events occurred during the study, 55 among patients assigned daily trimethoprim-sulfamethoxazole (2.1 per 100 person-years) and 56 among those assigned thrice-weekly treatment (2.1 per 100 person-years). The relative risk was 0.97 (95% CI, 0.66 -1.41; P ϭ .85). The cumulative percentages of patients developing PCP after 12, 24, and 36 months were 2.8%, 7.0%, and 10.1% for those assigned daily and 3.6%, 8.3%, and 11.9% for those assigned thrice-weekly trimethoprim-sulfamethoxazole (figure 1). A total of 231 confirmed or probable PCP events (including more than one event for 32 patients) were reported, 104 among patients assigned daily and 127 among those assigned thrice-weekly trimethoprim-sulfamethoxazole. Only one episode of extrapulmonary pneumocystosis was reported. While receiving originally assigned treatment or within 30 days of discontinuation, 28 patients assigned daily and 50 assigned thrice-weekly trimethoprim-sulfamethoxazole developed PCP (adjusted RR, 0.59; 95% CI, 0.37-0.95; P ϭ .03). In each treatment group, the majority of PCP events occurred after discontinuation of originally assigned treatment. The PCP risk was increased among patients who discontinued their assigned study dosage because of intolerance (overall: RR, 4.77; P Ͻ .001; for daily trimethoprim-sulfamethoxazole: RR, 3.68; P Ͻ .001; and for thrice-weekly trimethoprim-sulfamethoxazole: RR, 7.41; P Ͻ .001).
Toxoplasmosis. Of the 543 patients who were positive by serological testing for antibody to Toxoplasma at entry, 19 developed confirmed or probable toxoplasma encephalitis and 1 developed non-CNS toxoplasmosis. Based on 9 and 11 events in the daily and thrice-weekly trimethoprim-sulfamethoxazole groups, respectively, the rate of toxoplasmosis was 1.8 per 100 person-years in each group (table 2). An additional six patients (five with serological results negative for antibodies to toxoplasma at entry and one with missing serology) developed toxoplasmosis, bringing the total number of cases to 14 and 12 for the daily and thrice-weekly groups, respectively. NOTE. PCP reflects the first occurrence of confirmed or probable PCP after randomization. Primary ϭ patients receiving primary PCP prophylaxis; secondary ϭ patients receiving secondary PCP prophylaxis. Crude rates are per 100 person-years. Relative risks (RRs) and associated P values are based on proportional hazards regression model, stratified by unit and history of PCP at baseline and covariate adjusted for baseline CD4 ϩ cell count (square root scale) and prior progression of HIV disease (excluding PCP). CI ϭ confidence interval. * Includes only patients with antibody to Toxoplasma at randomization.
Death. In the daily trimethoprim-sulfamethoxazole treatment group, 557 patients died (20.8 per 100 person-years), and in the thrice-weekly group, 558 died (20.8 per 100 personyears). Unadjusted and adjusted relative risks were 1.00 (95% CI, 0.89 -1.13; P ϭ .94) and 0.91 (95% CI, 0.81-1.02; P ϭ .12) (table 2). PCP was reported as the cause of death for only 4.3% of study participants.
PCP or death. There was no difference in rates of PCP or death between patients receiving daily and thrice-weekly trimethoprim-sulfamethoxazole treatment (table 2) . Among patients in the daily treatment group, 589 died or acquired PCP (22.6 per 100 person-years), as did 591 patients in the thriceweekly group (22.8 per 100 person-years), producing an adjusted relative risk of 0.91 (95% CI, 0.81-1.02; P ϭ .10).
PCP or bacterial pneumonia. At least one new or recurrent episode of bacterial pneumonia was reported for 375 patients, 176 (7.6 per 100 person-years) assigned daily and 199 (8.6 per 100 person-years) assigned thrice-weekly trimethoprimsulfamethoxazole (adjusted RR, 0.82; 95% CI, 0.67-1.01; P ϭ .06) (table 2). When these bacterial pneumonia events were combined with all reported PCP events (irrespective of diagnostic certainty), 269 patients (11.9 per 100 person-years) assigned daily trimethoprim-sulfamethoxazole and 292 patients (13.1 per 100 person-years) assigned thrice-weekly trimethoprim-sulfamethoxazole experienced PCP or bacterial pneumonia (adjusted RR, 0.84; 95% CI, 0.71-1.00; P ϭ .04) (table 2) .
Discontinuation due to adverse events. In the daily group, 255 patients (19%), including 104 who changed to the thriceweekly dosage, discontinued the study-assigned dose of trimethoprim-sulfamethoxazole (13.9 per 100 person-years). These discontinuations were due to grade 1 toxicity in 14.5% of events, grade 2 toxicity in 44.3%, grade 3 toxicity in 23.1%, grade 4 toxicity in 17.6%, and grade 5 toxicity for one discontinuation. In the thrice-weekly group, 126 patients (9.6%) discontinued the study-assigned dose (6.3 per 100 person-years) (table 3). The discontinuations were due to grade 1 toxicity in 12.7% of events, grade 2 toxicity in 44.4%, grade 3 toxicity in 27.0%, and grade 4 toxicity in 15.9% of events. The adjusted relative risk (daily vs. thrice-weekly) for discontinuing the study-assigned dose was 2.14 (95% CI, 1.73-2.66; P Ͻ .001). Figure 2 shows the cumulative percentage of patients by treatment group who continued to receive their assigned study medication and did not discontinue medication because of adverse events. Permanent discontinuation (excluding switchovers) occurred among 169 patients (12.9%) assigned daily trimethoprim-sulfamethoxazole (8.7 per 100 person-years) (adjusted RR for daily vs. thrice-weekly trimethoprim-sulfamethoxazole: 1.36; P ϭ .01). Grade 4 adverse events occurred among 229 patients (12.9 per 100 person-years) assigned daily trimethoprim-sulfamethoxazole and 245 patients (12.9 per 100 person-years) assigned thrice-weekly trimethoprim-sulfamethoxazole (RR, 0.95; 95% CI, 0.79 -1.14; P ϭ .56). The most commonly reported toxicities requiring discontinuation were hypersensitivity reactions or rash (RR, 1.54; P ϭ .002); hema- tologic toxicities (RR, 4.52; P Ͻ .001); and gastrointestinal complications (RR, 2.34; P ϭ .02). Of study drug discontinuations due to hypersensitivity, 40% and 38% occurred within 1 month of randomization in patients assigned daily and thriceweekly trimethoprim-sulfamethoxazole, respectively.
A large proportion (70%) of study participants were receiving trimethoprim-sulfamethoxazole immediately before randomization, that is, at baseline. Irrespective of assigned trimethoprim-sulfamethoxazole dosage, rates of discontinuation during the study were higher for patients who were not using trimethoprim-sulfamethoxazole at baseline than for those who were using trimethoprim-sulfamethoxazole at baseline (12.3 vs. 8.9 per 100 person-years). Relative risks comparing discontinuation for the daily versus thrice-weekly dosage were similar for those with (RR, 2.31; P Ͻ .001) and without (RR, 1.91; P Ͻ .001) baseline trimethoprim-sulfamethoxazole use, both overall and for specific adverse events, including rash.
Subgroup analyses by history of PCP at baseline and other parameters. Table 2 displays overall results and those among patients receiving primary and secondary prophylaxis. As noted in figure 3, for each of the end points displayed, the adjusted relative risk (daily vs. thrice-weekly trimethoprimsulfamethoxazole) was Ͻ1, favoring daily trimethoprimsulfamethoxazole. The relative risk for each end point was smaller in the secondary prophylaxis subgroup than in the primary prophylaxis subgroup, indicating a larger treatment effect favoring daily dosage in the secondary group. However, there was no significant difference in the relative risks for any of the end points between the primary and secondary subgroups. The relative risk for discontinuation of assigned dosage because of intolerance among daily vs. thrice-weekly trimethoprim-sulfamethoxazole recipients was 2.17 (P Ͻ .001) and 1.94 (P ϭ .01) for primary and secondary prophylaxis groups, respectively.
No difference in relative effects of daily and thrice-weekly trimethoprim-sulfamethoxazole was noted in other subgroups, including those defined by baseline CD4 ϩ lymphocyte count, history of other AIDS (non-PCP) events, use of trimethoprimsulfamethoxazole at baseline, sex, race, and age.
Discussion
The superiority of trimethoprim-sulfamethoxazole for the prophylaxis of PCP is well-established [13] . However, to date no prospective study has been sufficiently powered to compare the efficacy and safety of daily vs. thrice-weekly trimethoprimsulfamethoxazole, two commonly used doses for the prevention of PCP [14] . This study, the largest ever conducted of primary and secondary PCP prophylaxis, demonstrated that PCP rates were similar with daily and thrice-weekly trimethoprim-sulfamethoxazole. However, as seen in figure 3, there were consistent trends in favor of daily trimethoprimsulfamethoxazole for PCP, death, bacterial pneumonia, and PCP or bacterial pneumonia. A smaller relative risk for PCP and higher event rates in the secondary prophylaxis group indicate a greater absolute risk reduction in this group compared with the primary prophylaxis group.
The major limitation of the widespread use of trimethoprimsulfamethoxazole has been the high rate of adverse events, especially with relatively high doses [10] . Two meta-analyses of randomized trials have assessed various doses of trimethoprim-sulfamethoxazole, primarily in comparison with other agents [9, 15] . One analysis noted a minimum discontinuation rate of 19 per 100 person-years with the use of trimethoprim-sulfamethoxazole [9] . The authors of these metaanalyses indicated that the data supported the use of lower doses of trimethoprim-sulfamethoxazole so as to improve tolerance without jeopardizing effectiveness. However, these findings are limited by the nature of the studies available for inclusion in the meta-analyses, including the small size of many of the studies, the lack of studies of lower-dose trimethoprim-sulfamethoxazole for secondary prophylaxis, and the availability of only three small comparative studies of two trimethoprim-sulfamethoxazole doses [5, 11, 12] .
In our study, trimethoprim-sulfamethoxazole was relatively well-tolerated, with rates of discontinuation lower than previously reported: only 11% of patients developed adverse events that necessitated discontinuation of study medication and 62% of the patients who survived until study closure continued to receive their assigned drug. In contrast, in another study in which a higher dose of trimethoprim-sulfamethoxazole was used (two double-strength tablets daily) and the use of zidovudine was required, only 21% of participants continued to take trimethoprim-sulfamethoxazole at the end of study. In a study that compared daily single-strength with daily double-strength trimethoprim-sulfamethoxazole, the total adverse event rate was 18% and 31%, respectively [8] . The lower overall adverse event rate noted in our study may reflect the use of antiretroviral agents other than zidovudine with less bone marrow suppression, the fact that a substantial percentage (70%) of participants were receiving trimethoprim-sulfamethoxazole at baseline, and the flexibility of the study design, which allowed clinicians to continue prescribing study drug for a patient if they deemed the adverse event unrelated to the study agent. Nonetheless, the rate of discontinuation of assigned dose due to intolerance was significantly higher among patients assigned daily than among those assigned thrice-weekly trimethoprimsulfamethoxazole. In addition, a higher risk of PCP (ϳ5-fold) was found among patients after discontinuation of assigned treatment. This finding may reflect that these patients were prescribed less effective alternative prophylactic regimens or that the population characterized by development of intolerance to trimethoprim-sulfamethoxazole was susceptible to the development of PCP for other reasons. Despite this higher intolerance rate for the patients receiving daily trimethoprimsulfamethoxazole and the increased risk of PCP noted after discontinuation of trimethoprim-sulfamethoxazole among all participants, the intent-to-treat analyses for all major efficacy end points still favored daily trimethoprim-sulfamethoxazole. Thus, the increased risk of discontinuation of daily trimethoprim-sulfamethoxazole due to intolerance was offset by the superior efficacy of daily vs. thrice-weekly trimethoprim-sulfamethoxazole for those who continued to receive their assigned dose. This finding is supported by both intent-to-treat and on-treatment analyses, although the latter must be interpreted cautiously, since it is not protected by randomization and more participants discontinued daily trimethoprimsulfamethoxazole because of toxicity. It is unlikely that the superior overall efficacy with the daily dose was due to better adherence with that dose, as adherence assessments done during the study showed similar rates of adherence in the two treatment groups.
In making a choice of the trimethoprim-sulfamethoxazole dose to be used, consideration should be taken of other factors, such as the effect on bacterial infections, toxoplasmosis, and survival. Bacterial pneumonia is a common complication of HIV disease and has been associated with significant morbidity and mortality [16] . Several studies have noted a beneficial effect of trimethoprim-sulfamethoxazole in the prevention of bacterial infections [4, 16, 17] . However, no prospective study had a sample size sufficient to assess the effect of different doses of trimethoprim-sulfamethoxazole in the prevention of bacterial pneumonia. Our study suggests that daily may be more effective than thrice-weekly trimethoprim-sulfamethoxazole in preventing bacterial pneumonia; the risk reduction was similar to that observed for PCP events (ϳ18%). PCP and bacterial pneumonia are the two most common serious respiratory complications of HIV disease [16] . The combined rate of PCP or bacterial pneumonia was 16% lower among patients receiving daily than among those receiving thrice-weekly trimethoprim-sulfamethoxazole. It is important to note that although bacterial pneumonia events were collected in a uniform manner, this was not a predetermined end point for this study and there may have been an ascertainment bias, as the two study treatments were not provided in a blinded manner.
Trimethoprim-sulfamethoxazole is also acknowledged as a superior prophylactic agent for PCP on the basis of its effectiveness in the prevention of toxoplasmosis [5, 15] . However, our study had too few toxoplasmosis events to enable comparison of the two doses. A recently reported case-control study showed that patients receiving low-dose trimethoprimsulfamethoxazole prophylaxis (fewer than four double-strength doses per week) were more likely to develop toxoplasmosis than were those receiving higher doses [18] .
PCP preventive therapy has been associated with improved survival [19, 20] . Bucher et al. [15] , in their meta-analysis, noted a favorable effect on survival with the use of trimethoprim-sulfamethoxazole for PCP prophylaxis. However, published observational studies are unlikely to reliably assess the effect of different doses of trimethoprimsulfamethoxazole on survival, and the prospective randomized studies were too small in sample size to compare the effect of various doses. In our study, among patients receiving secondary prophylaxis, those assigned daily trimethoprimsulfamethoxazole had significantly better survival than those assigned the thrice-weekly dose. This finding, however, should be interpreted with caution and may require confirmation by other studies.
This study was conducted largely before the widespread use of combination highly active antiretroviral therapy with its associated decrease in rates of development of PCP [21] . Whether the decrease in risk of PCP among patients receiving potent antiretroviral therapies will modify the comparative efficacy and safety of different doses of trimethoprimsulfamethoxazole is unknown. In a recently published decision analysis focused on different HIV disease progression rates, the choice of dose of trimethoprim-sulfamethoxazole or of alternate PCP prophylactic agents was assessed in terms of efficacy, toxicity, life expectancy, and cost [22] . The latter model was reported to support the use of low-dose trimethoprimsulfamethoxazole among those with slower disease progression rates (Ͼ3.8 years). However, data from clinical trials or other cohort studies are needed to address this issue.
In conclusion, this study, which enrolled a large population from a variety of demographic and geographic settings and in which a large proportion of the participants continued to receive their assigned study regimens, provides guidance for trimethoprim-sulfamethoxazole dosing options. The study showed that daily and thrice-weekly trimethoprim-sulfamethoxazole regimens were associated with similar rates of PCP. The estimates for all efficacy end points, however, favored daily trimethoprim-sulfamethoxazole, even though twice as many patients assigned to the daily dose discontinued trimethoprim-sulfamethoxazole or reduced their dose because of intolerance. The evidence favoring daily dosing was stronger for patients receiving secondary prophylaxis. The high rates of PCP observed after discontinuation of study drug support attempts to continue patients' receipt of trimethoprimsulfamethoxazole through dose reduction or desensitization when feasible [23, 24] and the need for more effective alternate prophylactic regimens. Taking all of the above factors into consideration, our study supports the use of daily trimethoprim-sulfamethoxazole as the dosing regimen of choice for PCP prophylaxis. Switching to thrice-weekly trimethoprim-sulfamethoxazole is an appropriate option for patients unable to tolerate the daily dose.
